Chinese Studies Changed the National Clinical Guideline for Stroke for the United Kingdom and Ireland

doi:10.3969/j.issn.1673-5765.2023.12.001

Abstract

Abstract: In 2023, the 2016 edition of the national clinical guideline for stroke for the United Kingdom and Ireland were updated 7 years after publication. Based on new research progress and the development of clinical techniques for diagnosis and treatment, this update version provides the latest diagnostic and treatment recommendations for clinical practice. It should be noted that, lots of evidence of the new edition came from Chinese clinical trials. Interpreting this guideline will help Chinese clinical doctors better understand international stroke diagnosis and treatment, enhance evidence-based awareness, and assist in the design and implementation of future international multicenter clinical trials.

Key words: Stroke; Guideline and consensus; Diagnosis; Treatment; Recommendation

摘要： 2023年，英国国家卒中临床指南（2016版）在发表后7年进行了更新。本次更新基于新的研究进展和临床诊疗技术的发展，为临床提供了最新的诊疗推荐意见。值得注意的是，推动本次英国国家卒中临床指南更新的多项临床研究来自中国。解读该指南，有助于我国临床医师了解卒中国际诊疗规范，提升循证意识，并为医师和研究者未来进行国际多中心临床研究的设计及实施提供帮助。

关键词: 卒中; 指南共识; 诊断; 治疗; 推荐意见

XIONG Yunyun, WANG Yongjun. Chinese Studies Changed the National Clinical Guideline for Stroke for the United Kingdom and Ireland[J]. Chinese Journal of Stroke, 2023, 18(12): 1337-1342.

熊云云, 王拥军. 中国研究改变英国卒中指南[J]. 中国卒中杂志, 2023, 18(12): 1337-1342.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.chinastroke.org.cn/EN/10.3969/j.issn.1673-5765.2023.12.001

https://www.chinastroke.org.cn/EN/Y2023/V18/I12/1337

References

[1] MENON B K，BUCK B H，SINGH N，et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada（AcT）：a pragmatic，multicentre，open-label，registry-linked，randomised，controlled，non-inferiority trial[J]. Lancet，2022，400（10347）：161-169.
[2] WANG Y J，LI S Y，PAN Y S，et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events（TRACE-2）：a phase 3，multicentre，open-label，randomised controlled，non-inferiority trial[J]. Lancet，2023，401（10377）：645-654.
[3] BERKHEMER O A，FRANSEN P S，BEUMER D，et al. A randomized trial of intraarterial treatment for acute ischemic stroke[J]. N Engl J Med，2015，372（1）：11-20.
[4] GOYAL M，DEMCHUK A M，MENON B K，et al. Randomized assessment of rapid endovascular treatment of ischemic stroke[J]. N Engl J Med，2015，372（11）：1019-1030.
[5] SAVER J L，GOYAL M，BONAFE A，et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke[J]. N Engl J Med，2015，372（24）：2285-2295.
[6] JOVIN T G，CHAMORRO A，COBO E，et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke[J]. N Engl J Med，2015，372（24）：2296-2306.
[7] CAMPBELL B C，MITCHELL P J，KLEINIG T J，et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection[J]. N Engl J Med，2015，372（11）：1009-1018.
[8] YANG P F，ZHANG Y W，ZHANG L，et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke[J]. N Engl J Med，2020，382（21）：1981-1993.
[9] ZI W J，QIU Z M，LI F L，et al. Effect of endovascular treatment alone vs intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke：the DEVT randomized clinical trial[J]. JAMA，2021，325（3）：234-243.
[10] SUZUKI K，MATSUMARU Y，TAKEUCHI M，et al. Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke：the SKIP randomized clinical trial[J]. JAMA，2021，325（3）：244-253.
[11] LECOUFFE N E，KAPPELHOF M，TREURNIET K M，et al. A randomized trial of intravenous alteplase before endovascular treatment for stroke[J]. N Engl J Med，2021，385（20）：1833-1844.
[12] FISCHER U，KAESMACHER J，STRBIAN D，et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke：an open-label，blinded-outcome，randomised non-inferiority trial[J]. Lancet，2022，400（10346）：104-115.
[13] MITCHELL P J，YAN B，CHURILOV L，et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5 h of stroke onset：an open-label，blinded-endpoint，randomised non-inferiority trial[J]. Lancet，2022，400（10346）：116-125.
[14] WANG Y J，WANG Y L，ZHAO X Q，et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med，2013，369（1）：11-19.
[15] JOHNSTON S C，EASTON J D，FARRANT M，et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA[J]. N Engl J Med，2018，379（3）：215-225.
[16] MA H，CAMPBELL B，PARSONS M W，et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke[J]. N Engl J Med，2019，380（19）：1795-1803.
[17] THOMALLA G，SIMONSEN C Z，BOUTITIE F，et al. MRI-guided thrombolysis for stroke with unknown time of onset[J]. N Engl J Med，2018，379（7）：611-622.
[18] ALBERS G W，MARKS M P，KEMP S，et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging[J]. N Engl J Med，2018，378（8）：708-718.
[19] NOGUEIRA R G，JADHAV A P，HAUSSEN D C，et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct[J]. N Engl J Med，2018，378（1）：11-21.
[20] WANG Y J，MENG X，WANG A X，et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med，2021，385（27）：2520-2530.
[21] JOHNSTON S C，AMARENCO P，DENISON H，et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA[J]. N Engl J Med，2020，383（3）：207-217.
[22] LIU X F，DAI Q L，YE R D，et al. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion（BEST）：an open-label，randomised controlled trial[J]. Lancet Neurol，2020，19（2）：115-122.
[23] LANGEZAAL L，VAN DER HOEVEN E，MONT'ALVERNE F，et al. Endovascular therapy for stroke due to basilar-artery occlusion[J]. N Engl J Med，2021，384（20）：1910-1920.
[24] TAO C R，NOGUEIRA R G，ZHU Y Y，et al. Trial of endovascular treatment of acute basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1361-1372.
[25] JOVIN T G，LI C H，WU L F，et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1373-1384.
[26] SAVER J L，CARROLL J D，THALER D E，et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke[J]. N Engl J Med，2017，377（11）：1022-1032.
[27] MAS J L，DERUMEAUX G，GUILLON B，et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke[J]. N Engl J Med，2017，377（11）：1011-1021.
[28] SONDERGAARD L，KASNER S E，RHODES J F，et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke[J]. N Engl J Med，2017，377（11）：1033-1042.
[29] YOSHIMURA S，SAKAI N，YAMAGAMI H，et al. Endovascular therapy for acute stroke with a large ischemic region[J]. N Engl J Med，2022，386（14）：1303-1313.
[30] SARRAJ A，HASSAN A E，ABRAHAM M G，et al. Trial of endovascular thrombectomy for large ischemic strokes[J]. N Engl J Med，2023，388（14）：1259-1271.
[31] HUO X C，Ma G T，Tong X，et al. Trial of endovascular therapy for acute ischemic stroke with large infarct[J]. N Engl J Med，2023，388（14）：1272-1283.
[32] BUCK B H，HILL M D，QUINN F R，et al. Effect of implantable vs prolonged external electrocardiographic monitoring on atrial fibrillation detection in patients with ischemic stroke：the PER DIEM randomized clinical trial[J]. JAMA，2021，325（21）：2160-2168.
[33] CONNOLLY S J，KARTHIKEYAN G，NTSEKHE M，et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation[J]. N Engl J Med，2022，387（11）：978-988.
[34] RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage（RESTART）：a randomised，open-label trial[J]. Lancet，2019，393（10191）：2613-2623.